Drugs / V590
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04569786 | Oct 2020 → Feb 2021 | COVID-19 | Merck Sharp & Dohme LLC | Terminated | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-01-25 | Merck Sharp & Dohme LLC | Results Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates merck.com ↗
In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-01-25 | Merck Sharp & Dohme LLC | Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates merck.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V590 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04569786 ↗ |
| Modality | Vaccine | “a live recombinant vesicular stomatitis virus-based COVID-19 vaccine candidate.” PMID 35809371 ↗ Jul 2022 |
| Route | Intramuscular | “administered via intramuscular (IM) injection” NCT04569786 ↗ |